title: CD4+CD161+ T lymphocytes infiltrate Crohn's disease-associated perianal fistulas and are reduced by anti-TNF-α local therapy.
abstract: BACKGROUND
  Crohn's disease (CD) is an idiopathic inflammatory bowel disease (IBD) in the pathogenesis of which both Th1 and Th17 lymphocytes have been described as being involved. The NK-associated molecule CD161 has recently been described as a marker of IL-17-producing lymphocytes. In this work we assessed the presence and the functional features of CD161 T helper lymphocytes infiltrating CD-associated perianal fistulas, both before and after inoculation of anti-TNF-α mAbs along the fistula.
  
  
  METHODS
  In a group of 9 CD patients with fistulizing perianal disease, we evaluated phenotypic and functional features of T cells recovered from the fistula, comparing them with peripheral blood (PB) T lymphocytes. Moreover, the effects anti-TNF-α mAbs injections along the fistula in terms of ability to reduce the inflammatory infiltrate and to determine fistula disappearance were assessed.
  
  
  RESULTS
  In CD patients with fistulizing disease there is an accumulation of CD161+ T helper lymphocytes, with higher frequencies of Th1, Th17 and Th17/Th1 cells in the fistula than in PB. Local anti-TNF-α administration is associated with fistula resolution in the majority of patients with disappearance of infiltrating T lymphocytes, without any systemic effect in circulating effector T cells.
  
  
  CONCLUSIONS
  These findings suggest that CD4+CD161+ T cells with Th17, Th17/Th1 and Th1 phenotype accumulate in CD perianal fistulas, and indicate local anti-TNF-α mAbs administration along the fistula as a promising tool for the treatment of these patients.
authors.affiliation: Center for Research, Transfer and High Education DENOTHE, University of Florence, Florence, Italy.
authors.forename: Laura
authors.initials: L
authors.lastname: Maggi
authors.forename: Manuela
authors.initials: M
authors.lastname: Capone
authors.forename: Francesco
authors.initials: F
authors.lastname: Giudici
authors.forename: Veronica
authors.initials: V
authors.lastname: Santarlasci
authors.forename: Valentina
authors.initials: V
authors.lastname: Querci
authors.forename: Francesco
authors.initials: F
authors.lastname: Liotta
authors.forename: Ferdinando
authors.initials: F
authors.lastname: Ficari
authors.forename: Enrico
authors.initials: E
authors.lastname: Maggi
authors.forename: Francesco
authors.initials: F
authors.lastname: Tonelli
authors.forename: Francesco
authors.initials: F
authors.lastname: Annunziato
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Cosmi
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000473:pathology; D003424:Crohn Disease / Q000097:blood / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008297:Male; D008875:Middle Aged; D055651:NK Cell Lectin-Like Receptor Subfamily B / Q000276:immunology*; D012003:Rectal Fistula / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D055651:NK Cell Lectin-Like Receptor Subfamily B; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab